Wanbury Share Price & Earnings Call Analysis

Financials of Wanbury

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Wanbury

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +126133146144146139131161133172163160162
Expenses +119119133127124121120141120142139134136
Operating Profit6141317211811201430242627
OPM %5%11%9%12%15%13%8%12%10%17%15%16%16%
Other Income +0-311111212000
Interest786887810109877
Depreciation3333333333444
Profit before tax-315710818119141516
Tax %8%-11%6%-2%-0%3%0%2%5%-6%1%-0%1%
Net Profit +-315710818120131516
EPS in Rs-1.000.311.432.253.142.470.322.450.376.184.104.354.52

Financials of Wanbury

Profit & Loss

Annual income statement trend

Sep 2014 18mMar 2015 6mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +661250420432370391367392511500578600658
Expenses +620228387414438375344374475476506523551
Operating Profit41213419-6816231836237277107
OPM %6%9%8%4%-18%4%6%5%7%5%12%13%16%
Other Income +-2376090769842770133
Interest48193236314033232121293731
Depreciation235910101010101112131314
Profit before tax-2674-762-32-2565-1281-10313064
Tax %1%28%0%1%-1%-1%0%2%-0%1%1%-3%
Net Profit +-2703-762-32-2564-1381-10303165
EPS in Rs-135.211.61-3.5226.71-13.49-10.4825.79-5.0424.94-3.189.289.3219.15
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Wanbury

Balance Sheet

Capital structure and asset base

Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital20202023242425253333333335
Reserves-186-188-183-151-183-207-143-156-30-40-52672
Borrowings +3893813732732242331641667468116179196
Other Liabilities +182182176265207235231253275241199176153
Total Liabilities404394386411271285277288351302343414457
Fixed Assets +174164180186178172164167167167167201199
CWIP131914101091411223513
Investments0000000000000
Other Assets +2182121922158310399109182133173208244
Total Assets404394386411271285277288351302343414457

Financials of Wanbury

Cash Flows

Operating, investing and financing cash movement

Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +74404343323044174120526
Cash from Investing Activity +-7-5-20-13-1-36481-9-17-51
Cash from Financing Activity +-75-30-28-27-33-27-108-17-29-321426
Net Cash Flow-95-53-2-0-0713-2121
Free Cash Flow6235222930253612427-9-23
CFO/OP180%187%129%234%-49%188%188%97%113%86%7%35%

Financials of Wanbury

Ratios

Working capital efficiency and return ratios

Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days5714465712941503245505670
Inventory Days4210369632736254160264347
Days Payable112300171259173208252220218178196172
Cash Conversion Cycle-13-54-37-124-117-131-176-147-112-101-96-55
Working Capital Days-44-139-123-164-251-230-211-227-134-129-374
ROCE %6%12%55%-1%26%31%23%46%17%58%34%

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd